Abstract
Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) have changed the paradigm of treatment in non-small cell lung cancer (NSCLC). The molecular biology study of EGFR has led to clinical trials that select patients more accurately, regarding the presence of EGFR activating mutations. Nonetheless, a lack of response or a temporary condition of the response has been detected in patients on EGFR TKIs. This has urged to study potential resistance mechanisms underneath. The most important ones are the presence of secondary mutations in EGFR, such as T790M, or the overexpression of mesenchymal-epithelial transition factor (MET) that may explain why patients who initially respond to EGFR TKIs, may ultimately become refractory. Several approaches have been taken and new drugs both targeting EGFR resistance-mutation or MET are currently being developed. Here we review and update the EGFR biological pathway as well as the clinical data leading to approval of the EGFR TKIs currently in the market. New compounds under investigation targeting resistance mutations or dually targeting EGFR and other relevant receptors are also reviewed and discussed.
Keywords: Activity mutations, epidermal growth factor receptor, tyrosine kinase inhibitors.
Current Drug Targets
Title:Epidermal Growth Factor Receptor Targeting in Non-Small Cell Lung Cancer: Revisiting Different Strategies Against the Same Target
Volume: 15 Issue: 14
Author(s): Eduardo Castanon, Patricia Martin, Christian Rolfo, Juan P. Fusco, Lucia Ceniceros, Jairo Legaspi, Marta Santisteban and Ignacio Gil-Bazo
Affiliation:
Keywords: Activity mutations, epidermal growth factor receptor, tyrosine kinase inhibitors.
Abstract: Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) have changed the paradigm of treatment in non-small cell lung cancer (NSCLC). The molecular biology study of EGFR has led to clinical trials that select patients more accurately, regarding the presence of EGFR activating mutations. Nonetheless, a lack of response or a temporary condition of the response has been detected in patients on EGFR TKIs. This has urged to study potential resistance mechanisms underneath. The most important ones are the presence of secondary mutations in EGFR, such as T790M, or the overexpression of mesenchymal-epithelial transition factor (MET) that may explain why patients who initially respond to EGFR TKIs, may ultimately become refractory. Several approaches have been taken and new drugs both targeting EGFR resistance-mutation or MET are currently being developed. Here we review and update the EGFR biological pathway as well as the clinical data leading to approval of the EGFR TKIs currently in the market. New compounds under investigation targeting resistance mutations or dually targeting EGFR and other relevant receptors are also reviewed and discussed.
Export Options
About this article
Cite this article as:
Castanon Eduardo, Martin Patricia, Rolfo Christian, Fusco P. Juan, Ceniceros Lucia, Legaspi Jairo, Santisteban Marta and Gil-Bazo Ignacio, Epidermal Growth Factor Receptor Targeting in Non-Small Cell Lung Cancer: Revisiting Different Strategies Against the Same Target, Current Drug Targets 2014; 15 (14) . https://dx.doi.org/10.2174/138945011514141216092935
DOI https://dx.doi.org/10.2174/138945011514141216092935 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bifunctional siRNA Containing Immunostimulatory Motif Enhances Protection Against Pandemic H1N1 Virus Infection
Current Gene Therapy Pharmaceutical Inhibition of Neddylation as Promising Treatments for Various Cancers
Current Topics in Medicinal Chemistry Novel Marine-Derived Anti-Cancer Agents
Current Pharmaceutical Design The Use of Mathematical Modelling for Improving the Tissue Engineering of Organs and Stem Cell Therapy
Current Stem Cell Research & Therapy Clinical Trials Targeting Advanced Cancers by Active Immunization of T-cell Defined Tumor Antigens
Current Pharmaceutical Design Therapeutic and Diagnostic Applications of Nanoparticles
Current Drug Targets Biodegradable Polymeric Nanoparticles as the Delivery Carrier for Drug
Current Drug Delivery Cannabinoids and Psychosis
Current Pharmaceutical Design Namitecan: a Hydrophilic Camptothecin with a Promising Preclinical Profile
Current Medicinal Chemistry Interaction of Biologically Active Amines with Mitochondria and Their Role in the Mitochondrial-Mediated Pathway of Apoptosis
Current Medicinal Chemistry Synthesis, DNA Binding Ability and Anticancer Activity of 2-heteroaryl Substituted Benzimidazoles Linked Pyrrolo[2,1-c][1,4]benzodiazepine Conjugates
Medicinal Chemistry Mechanisms of Action of Imidazoacridinone and Triazoloacridinone Derivatives in View of their Biological Activity
Current Pharmaceutical Analysis Camptothecins and Topoisomerase I; A Foot in the Door. Targeting the Genome Beyond Topoisomerase I with Camptothecins and Novel Anticancer Drugs; Importance of DNA Replication, Repair and Cell Cycle Checkpoints
Current Medicinal Chemistry - Anti-Cancer Agents Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents
Anti-Cancer Agents in Medicinal Chemistry Multi-Targeted Agents in Cancer Cell Chemosensitization: What We Learnt from Curcumin Thus Far
Recent Patents on Anti-Cancer Drug Discovery Antitumoral Activity of Interferon-γ Involved in Impaired Immune Function in Cancer Patients
Current Drug Metabolism Patient Perspectives in OMERACT Provide an Anchor for Future Metric Development and Improved Approaches to Healthcare Delivery in Connective Tissue Disease Related Interstitial Lung Disease (CTD-ILD)
Current Respiratory Medicine Reviews Underexpression of miR-486-5p but not Overexpression of miR-155 is Associated with Lung Cancer Stages
MicroRNA A Comprehensive Review on Perfusion Method Development for Bone Marrow Collection and Stem Cell Transplantation
Current Stem Cell Research & Therapy MicroRNA-31 Inhibits Lung Adenocarcinoma Stem-Like Cells via Down-Regulation of MET-PI3K-Akt Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry